Ngelheim) and Susan Stasiuk (University of Calgary). Quite small would have been possible without having the generous support of our sponsors, who helped us maintain our tradition of affordability Bayer Animal Well being, Boehringer Ingelheim, Zoetis and New England Biolabs. Thank you to all of you. Conflicts of interest The authors declare no conflict of interest.
International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 297eContents lists out there at ScienceDirectInternational Journal for Parasitology: Drugs and Drug Resistancejournal homepage: www.elsevier.com/locate/ijpddrInvited ArticleAnthelmintics: From discovery to resistance II (San Diego, 2016)Richard J. Martin a, , Adrian J. Wolstenholme b, Conor R. Caffrey cDepartment of Biomedical Sciences, Iowa State University, Ames, IA 50011, USA Department of Infectious Ailments, University of Georgia, Athens, GA 30602, USA c Center for Discovery and Innovation in Parasitic Ailments Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USAb aa r t i c l e i n f oArticle history: Received 21 1-Phenylethan-1-One Purity September 2016 Accepted 22 September 2016 Obtainable on the web 29 September 2016 Keywords: Anthelmintics Resistance Drug discovery Scientific meeting San Diegoa b s t r a c tThe second scientific meeting within the series: “Anthelmintics: From Discovery to Resistance” was held in San Diego in February, 2016. The focus subjects of your meeting, related to anthelmintic discovery and resistance, have been novel technologies, bioinformatics, commercial interests, anthelmintic modes of action and anthelmintic resistance. Basic scientific, human and veterinary interests had been addressed in oral and poster presentations. The delegates were from universities and industries within the US, Europe, Australia and New Zealand. The papers were a fantastic representation on the field, and integrated the usage of C. elegans for lead discovery, mechanisms of anthelmintic resistance, nematode neuropeptides, proteases, B. thuringiensis crystal protein, nicotinic receptors, emodepside, benzimidazoles, Pglycoproteins, natural goods, microfluidic strategies and bioinformatics approaches. The NIH also presented NIAIDspecific parasite genomic priorities and initiatives. From these papers we introduce beneath chosen papers with a focus on anthelmintic drug screening and improvement.
The meeting followed its predecessor: `Anthelmintics: Discovery to Resistance’ that took location in San Francisco, in February, 2016 (Wolstenholme and Martin, 2014) and an earlier meeting on helminth Acidogenesis pathway Inhibitors products ionchannels in Philadelphia in December, 2011 (Wolstenholme, 2012). With this San Diego meeting we wanted to continue the idea of bringing with each other biologists, pharmacologists, veterinarians, physicians and discovery scientists from universities and market, who share interests in anthelmintic discovery and resistance. We also wanted to foster the improvement and futures of graduate students functioning in the area of anthelmintic research. Corresponding author. Email address: [email protected] (R.J. Martin).We anticipated that we would attract around 80 delegates initially, but sooner or later secured more than 100 delegates, which was a crucial encouragement to all of us. The meeting was held in the Marina Village Center in San Diego which provided a really welcome sunny and warm location in contrast to the winter cold which most delegates came. The location and accommodation worked quite well, enabling great discus.
